Department of Pathology, Siberian State Medical University Ministry of Health of Russia, Tomsk 634050, Russia.
Department of General and Molecular Pathology, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk 634009, Russia.
J Zhejiang Univ Sci B. 2022 Aug 15;23(8):617-624. doi: 10.1631/jzus.B2200113.
According to the classification presented by Lehmann BD (2016), triple-negative breast cancer (TNBC) is a heterogeneous group of malignant tumors with four specific subtypes: basal-like (subtype 1 and subtype 2), mesenchymal, and luminal androgen receptor (LAR) subtypes. The basal-like subtypes of carcinomas predominate in this group, accounting for up to 80% of all cases. Despite the significantly lower proportions of mesenchymal and LAR variants in the group of breast carcinomas with a TNBC profile, such tumors are characterized by aggressive biological behavior. To this end, the LAR subtype is of particular interest, since the literature on such tumors presents different and even contradictory data concerning the disease course and prognosis. This review is devoted to the analysis of the relevant literature, reflecting the main results of studies on the molecular properties and clinical features of the disease course of LAR-type TNBC carcinomas.
根据 Lehmann BD（2016）提出的分类，三阴性乳腺癌（TNBC）是一组具有四种特定亚型的恶性肿瘤：基底样（亚型 1 和亚型 2）、间充质和腔面雄激素受体（LAR）亚型。在该组中，基底样癌亚型占主导地位，占所有病例的高达 80%。尽管在 TNBC 特征的乳腺癌组中，间充质和 LAR 变体的比例明显较低，但此类肿瘤的生物学行为具有侵袭性。为此，LAR 亚型特别有趣，因为有关此类肿瘤的文献提供了关于疾病过程和预后的不同甚至相互矛盾的数据。本综述致力于分析相关文献，反映了关于 LAR 型 TNBC 癌的分子特性和疾病过程临床特征的主要研究结果。
